EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biomarker‐Based Diagnosis and Care Pathways for Alzheimer's Disease in the Era of Disease‐Modifying Treatments: A Consensus Statement by Belgian Experts

Tim Van Langenhove, Sara Van Mossevelde, Marijke Miatton, Jan De Lepeleire, Rose Bruffaerts, Jean Christophe Bier, Kurt Segers, Jurn Verschraegen, Mirko Petrovic iD, Manfredi Ventura, Haroun Jedidi, Ingo Beyer und 20 weitere

European Journal of Neurology · 2026-08 · 33 (8)

DOI: 10.1111/ene.70668 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 31.07.2026. Verfasst von Tim Van Langenhove und 31 weiteren Autor:innen. Beteiligte Einrichtung: Cognitive Center, Department of Neurology, Ghent University Hospital, Ghent, Belgium. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The recent approval of disease‐modifying therapies (DMTs) for early Alzheimer's disease (AD) marks a major shift in clinical practice. Biomarker confirmation of amyloid pathology is now required alongside clinical assessment, and blood‐based tests are improving accessibility. This creates increased demand for timely and accurate diagnosis while avoiding overdiagnosis in low‐probability cases. This Belgian consensus aims to guide biomarker‐based diagnosis of AD in the era of DMTs and to highlight the system adaptations required for safe and equitable implementation. Belgium, with universal healthcare but regionally organised dementia care, provides a relevant case to illustrate both opportunities and challenges.

Methods

This consensus was developed by 31 experts in cognitive neurology, geriatrics, neuropsychology, neuroimaging, neurochemistry, and primary care, coordinated by the Belgian Dementia Council (BeDeCo). Recommendations were based on multidisciplinary discussion, current evidence, and the organisation of dementia care in Belgium.

Results

The consensus outlines a stepwise diagnostic approach that integrates clinical assessment with biomarker confirmation using cerebrospinal fluid, amyloid‐PET, and emerging blood‐based tests. We review the strengths and limitations of each modality and provide guidance for use across clinical scenarios. Using Belgium as a case example, we illustrate challenges that are shared across European healthcare systems, such as limited reimbursement, unequal access to expertise, and insufficient diagnostic capacity, and formulate pragmatic recommendations to address these issues.

Conclusions

This consensus offers practical guidance for embedding biomarker‐based diagnostic strategies into clinical care. By outlining structured pathways and system‐level priorities, it facilitates safe, feasible, and equitable implementation of DMTs for AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBiomarkersHumansBelgium

Stichwörter der Autor:innen

Alzheimer's diseasebiomarkerscare pathwaysdiagnosisdisease‐modifying therapy

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Cognitive Center, Department of Neurology, Ghent University Hospital, Ghent, Belgium.
  • Department of Neurology, University Hospital of Antwerp, Antwerp, Belgium.
  • Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
  • Department of Public Health and Primary Care, Academic Center for General Practice, KU Leuven, Leuven, Belgium.
  • Computational Neurology, Experimental Neurobiology Unit (ENU), Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
  • Biomedical Research Institute, Hasselt University, Hasselt, Belgium.

ORCID-Profile: Mirko Petrovic, Eric Mormont, Gert Cypers, Jan Versijpt, Maria Bjerke, Bernard Hanseeuw

Zitieren

APA

Van Langenhove, T., Van Mossevelde, S., Miatton, M., De Lepeleire, J., Bruffaerts, R., Bier, J. C., Segers, K., Verschraegen, J., Petrovic, M., Ventura, M., Jedidi, H., Beyer, I., Mormont, E., Vandenberghe, R., Delva, A., Gilles, C., Van Weehaeghe, D., Picard, G., De Deyn, P., …, & BeDeCo members (2026). Biomarker‐Based Diagnosis and Care Pathways for Alzheimer's Disease in the Era of Disease‐Modifying Treatments: A Consensus Statement by Belgian Experts. European Journal of Neurology, 33(8). https://doi.org/10.1111/ene.70668

Vancouver

Van Langenhove T, Van Mossevelde S, Miatton M, De Lepeleire J, Bruffaerts R, Bier JC, et al. Biomarker‐Based Diagnosis and Care Pathways for Alzheimer's Disease in the Era of Disease‐Modifying Treatments: A Consensus Statement by Belgian Experts. European Journal of Neurology. 2026;33(8). doi:10.1111/ene.70668

BibTeX
@article{VanLangenhove2026,
  author = {Van Langenhove, Tim and Van Mossevelde, Sara and Miatton, Marijke and De Lepeleire, Jan and Bruffaerts, Rose and Bier, Jean Christophe and Segers, Kurt and Verschraegen, Jurn and Petrovic, Mirko and Ventura, Manfredi and Jedidi, Haroun and Beyer, Ingo and Mormont, Eric and Vandenberghe, Rik and Delva, Aline and Gilles, Christian and Van Weehaeghe, Donatienne and Picard, Gaëtane and De Deyn, Peter and Strauss, Mélanie and Thiery, Evert and Salmon, Eric and Cypers, Gert and Vlaemynck, Joris and Gillis, Katrin and Versijpt, Jan and Bjerke, Maria and Sieben, Anne and Hanseeuw, Bernard and Engelborghs, Sebastiaan and Deryck, Olivier and BeDeCo members, BeDeCo members},
  title = {Biomarker‐Based Diagnosis and Care Pathways for Alzheimer's Disease in the Era of Disease‐Modifying Treatments: A Consensus Statement by Belgian Experts},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {8},
  doi = {10.1111/ene.70668}
}
Kostenlos starten →